SEC Form 4 · accession 0001179110-17-004739

Blueprint Medicines Corp · BPMC

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — Chief Business Officer

Period of report

Mar 14, 2017

Accepted (ET)

Mar 16, 2017 · 5:36 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001597264

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 14, 2017	M	12,714	$16.28	A	12,714	D
Common Stock^F3	Mar 14, 2017	S	12,714	$40.01	D	0	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$16.28	Mar 14, 2017	M	12,714	D	—	Feb 1, 2026	Common Stock	12,714	87,286	D

F1The exercise reported on this Form 4 was effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Exchange Act.
F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.77 to $40.27 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4This option was granted on February 1, 2016. This option vests with respect to 25% of the shares underlying the option on January 5, 2017 and as to an additional 1/48th of the shares underlying the option each month thereafter.